title: Mitoxantrone as a potential therapy for primary progressive multiple sclerosis.
abstract: Mitoxantrone (Novantrone) was the first drug approved in western Europe and North America for treatment of secondary progressive multiple sclerosis (SPMS) and progressive relapsing MS (PRMS). Pharmacological properties of mitoxantrone, its role in SPMS, the study rational and design of an ongoing multi-centre, double blind, randomized, placebo-controlled phase 2 trial will be outlined in this article.
authors.affiliation: Department of Neurology, University of California, San Francisco, 521 Parnassus Avenue, C-440, San Francisco, CA 94143-0114, USA.
authors.forename: Olaf
authors.initials: O
authors.lastname: Stüve
authors.forename: Mariko
authors.initials: M
authors.lastname: Kita
authors.forename: Daniel
authors.initials: D
authors.lastname: Pelletier
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Fox
authors.forename: Jerome
authors.initials: J
authors.lastname: Stone
authors.forename: Donald E
authors.initials: DE
authors.lastname: Goodkin
authors.forename: Scott S
authors.initials: SS
authors.lastname: Zamvil
mesh_terms: D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008942:Mitoxantrone / Q000627:therapeutic use*; D020528:Multiple Sclerosis, Chronic Progressive / Q000188:drug therapy*
chemical_list: D007166:Immunosuppressive Agents; D008942:Mitoxantrone